©2024 Stanford Medicine
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Not Recruiting
Trial ID: NCT06087029
Purpose
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR
plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or
major aortic complications compared to an upfront conservative strategy of medical therapy
with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Official Title
IMPRoving Outcomes in Vascular DisEase- Aortic Dissection
Stanford Investigator(s)
Dominik Fleischmann
Professor of Radiology (Cardiovascular Imaging)
Eligibility
Inclusion Criteria:
1. Age > 21 years
2. Stanford type B aortic dissection not involving the aorta at or proximal to the
innominate artery, without rupture and/or malperfusion (renal, mesenteric, or
extremity)
3. Acuity: within 48 hours - 6 weeks of index admission
4. Ability to provide written informed consent and comply with the protocol
Exclusion Criteria:
1. Ongoing systemic infection
2. Pregnant or planning to become pregnant in the next 3 months
3. Life expectancy related to non-aortic conditions < 2 years
4. Unwilling or unable to comply with all study procedures including serial imaging
follow-up
5. Known patient history of genetic aortopathy
6. Penetrating Aortic Ulcer and Intramural hematoma
7. Iatrogenic (traumatic) aortic dissection
8. Previous aortic dissection or aortic surgery
9. Prior aortic aneurysmal disease
Intervention(s):
procedure: TEVAR
other: Guideline directed medical therapy and surveillance of dissection
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305